Filgrastim biosimilar - Adello Biologics

Drug Profile

Filgrastim biosimilar - Adello Biologics

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Therapeutic Proteins International
  • Developer Adello Biologics
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Neutropenia

Most Recent Events

  • 11 Sep 2017 Preregistration for Neutropenia in USA (unspecified route) before September 2017
  • 11 Sep 2017 US FDA accepts BLA for filgrastim biosimilar for Neutropenia for review
  • 16 Nov 2016 Therapeutic Proteins International is now called Adello Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top